BETA Stock View

Beta Drugs Ltd
stock-view-header

₹ 1,000

Market Cap ₹( Cr.)
9,613.79
Proj. P/E (x)
Proj. P/BV (x)
Proj. ROE (%)
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)

Stock View

Last Updated On.
24-Sep-2023
 

The average score for Beta Drugs Ltd stands at against , three months back.

Beta Drugs Limited is an India-based company that is engaged in the business of manufacturing of oncology medicines. The Company offers a range of oncology products including tablets, capsules and injections. The Company offers a portfolio consisting of approximately 50 products catering to various oncology diseases, including breast, brain, bone, lung, mouth, head and neck, prostate, leukemia, lymphoma and supportive cancer and others. The Company’s oncology portfolio includes various brands, such as AB-PACLI, ADBIRON, ADCARB, ADCIST, Adlante, ADLEAP, ADMIDE, ADOXI, CAPAD, ADTHAL, Triodelta and others.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.



Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required